Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the Development of Transformative Medicines for Chronic Inflammatory Diseases

Nov 18, 2020•over 4 years ago

Amount Raised

$12 Million

Round Type

seed

Los Altos

Description

Evommune, Inc., an innovation engine in chronic inflammation, announced the successful completion of a $12.5 million seed financing by Pivotal bioVenture Partners. This financing will enable Evommune to build a pipeline of unique therapies for patients with chronic inflammatory diseases.

Company Information

Company

Evommune, Inc.

Location

Los Altos, California, United States

About

Evommune is a private, R&D company and innovation engine in chronic inflammation. Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, California. For more information please visit Evommune.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the Development of Transformative Medicines for Chronic Inflammatory Diseases

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information